[LOGO]

Company Contacts:                       Investor Relations Contacts:
E-Z-EM, Inc.                            Lippert/Heilshorn & Associates, Inc.
------------                            ------------------------------------
Tom Johnson (tjohnson@ezem.com)         Kim Sutton Golodetz (kgolodetz@lhai.com)
(800) 544-4624 x3317                    (212) 838-3777
www.ezem.com                            Bruce Voss (bvoss@lhai.com)
                                        (310) 691-7100

FOR IMMEDIATE RELEASE

                     E-Z-EM BOARD DECLARES SPECIAL DIVIDEND
                             OF ANGIODYNAMICS SHARES

LAKE SUCCESS, N.Y., August 19, 2004--E-Z-EM, Inc., (AMEX: EZM) today announced
that its Board of Directors has declared a special stock dividend of the 9.2
million shares of common stock of its subsidiary AngioDynamics, Inc., (Nasdaq
NM: ANGO) held by E-Z-EM. The special stock dividend is payable on October 30,
2004 to E-Z-EM shareholders of record on October 11, 2004, and will mark the
completion of AngioDynamics' spin-off from E-Z-EM.

E-Z-EM has received a private letter ruling from the Internal Revenue Service
that the dividend will be tax-free for federal income tax purposes to E-Z-EM and
its stockholders, except for any cash received by stockholders instead of a
fractional share. The payout ratio will be determined on the record date.

About E-Z-EM, Inc.

E-Z-EM is a leading manufacturer of contrast agents for gastrointestinal
radiology. The Company has developed the only CT injector on the market that can
help detect contrast extravasation, the EmpowerCT(R) with patented EDA(TM)
technology; it also offers a complete product set for the virtual colonoscopy
practitioner. This product line consists of virtual colonoscopy hardware,
software, nutritional prep kits and bowel cleaners, tagging agents and a carbon
dioxide colon insufflation system.

About AngioDynamics

AngioDynamics, Inc. (www.angiodynamics.com) designs, develops, manufactures and
markets innovative medical devices used in minimally invasive, image-guided
procedures to treat peripheral vascular disease. It offers a broad line of
therapeutic and diagnostic devices that enable interventional physicians, such
as interventional radiologists, vascular surgeons and others, to treat
peripheral vascular diseases and other non-coronary diseases. The Company's
diverse product line includes angiographic catheters, hemodialysis catheters,
endovascular laser venous system products, PTA dilation balloon catheters,
image-guided vascular access products, thrombolytic products, and drainage
products.

The statements made in this document contain certain forward-looking statements
that involve a number of risks and uncertainties. Words such as "expects",
"intends", "anticipates", "plans", "believes", "seeks", "estimates," or
variations of such words and similar expressions, are intended to identify such
forward-looking statements. Investors are cautioned that actual events or
results may differ from the Company's expectations. In addition to the matters
described above, the ability of the Company to develop its products, market
acceptance and sales of VoLumenTM, future actions by the FDA or other regulatory
agencies, results of pending or future clinical trials, overall economic
conditions, general market conditions, market acceptance, foreign currency
exchange rate fluctuations, the effects on pricing from Group Purchasing
Organizations, competition, including alternative procedures which continue to
replace traditional fluoroscopic procedures, as well as the risk factors listed
from time to time in the SEC filings of E-Z-EM, Inc., including but not limited
to its Form 10-Q for the quarter ended February 29, 2004, as well as its Annual
Report on Form 10-K for the year ended May 31, 2003, and in the S-1 Registration
Statement filed by AngioDynamics in connection with its public offering, may
affect the actual results achieved by E-Z-EM and AngioDynamics.

                                      # # #